BioSpace News Archive

DERMALA, Inc., a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million Series A financing.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1 antigen.

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced new results from ASPEN-01, the ALX148 Phase 1b study, evaluating patients with solid tumor malignancies at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting [abstract 404].

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Company is expanding its clinical program for vosoritide, an investigational analog of C-type Natriuretic Peptide (CNP), with two new Phase 2 studies.

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2020, ended August 31, 2020, after the close of the financial markets on Monday, November 16, 2020.

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announced the launch of an Inovalon ONE® Platform configuration supporting multiple national vaccine adherence initiatives.

Results demonstrated that ADAIR had slower absorption and lower early exposure, and was less desirable to recreational drug abusers on key measures of abuse liability compared to commercially available dextroamphetamine Safety profile consistent with known effects of stimulants with no new safety or tolerability signals identified

Surface Oncology (Nasdaq: SURF), today announced that preclinical data on SRF388, a first in class IL-27 blocking antibody in clinical trials for patients with cancer, and SRF114, a CCR8-selective antibody, will be presented at the Society for Immunotherapy for Cancer’s (SITC) 35th Anniversary Annual Meeting

Disparities in unilateral knee replacement surgery have been well-documented, with lower utilization and higher complication rates among African American patients.

ProTec 99 is the solution for quick and affordable sterilization in a wide variety of areas. This patent-pending product employs proprietary technology in a handheld device that allows the user to scan surfaces while emitting powerful UV-C radiation.